RxDoctor Payments Data

Charlotte Vermeulen

Family · New Kensington, PANPI 1225469901

Payments from drug & device makers

$3,002in general payments, 2019–2025

Across 177 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$618
  • GSK$478
  • Lilly USA, LLC$275
  • Abbott$260
  • AbbVie$234
  • Exact Sciences$172
  • plus $965 from 15 others

What the payments were for

  • Food & beverage$3,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,002 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$124,093
OzempicSemaglutide88$92,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$54,571
TrulicityDulaglutide24$27,966
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$25,049
JanuviaSitagliptin Phosphate18$16,318
EliquisApixaban13$13,886
XareltoRivaroxaban16$13,324
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$12,912
Tresiba Flextouch U-200Insulin Degludec11$12,607
Advair HfaFluticasone Propion/Salmeterol34$12,425
Stiolto RespimatTiotropium Br/Olodaterol Hcl25$11,539
Soliqua 100-33Insulin Glargine/Lixisenatide12$9,743
Aimovig AutoinjectorErenumab-Aooe13$9,240
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$7,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$165$135,632141 claims
Novo NordiskOzempic$618$92,44388 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$478$86,058149 claims
Lilly USA, LLCTrulicity$275$27,96624 claims
MerckJanuvia$87$16,31818 claims
PfizerEliquis$89$13,88613 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$98$9,74312 claims
AbbVieSynthroid$234$92111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in New Kensington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →